Related references
Note: Only part of the references are listed.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Evolocumab for Early Reduction of LDL Cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS)
Konstantinos C. Koskinas et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Safety and Incidence of Cardiovascular Events in Chinese Patients with Acute Coronary Syndrome Treated with Ticagrelor: the 12-Month, Phase IV, Multicenter, Single-Arm DAYU Study
Runlin Gao et al.
CARDIOVASCULAR DRUGS AND THERAPY (2018)
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Robert P. Giugliano et al.
CIRCULATION (2018)
Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels A Meta-analysis
Marc S. Sabatine et al.
JAMA CARDIOLOGY (2018)
Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial
Konstantinos C. Koskinas et al.
CLINICAL CARDIOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Safety and Efficacy of Extremely Low LDL-Cholesterol Levels and Its Prospects in Hyperlipidemia Management
Dhrubajyoti Bandyopadhyay et al.
JOURNAL OF LIPIDS (2018)
Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins
Kathleen M. Fox et al.
CLINICAL RESEARCH IN CARDIOLOGY (2018)
SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study
Ju-E Liu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
Robert P. Giugliano et al.
LANCET (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Hierarchical Porous Chitosan Sponges as Robust and Recyclable Adsorbents for Anionic Dye Adsorption
Mei Wang et al.
SCIENTIFIC REPORTS (2017)
Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
Marc S. Sabatine et al.
AMERICAN HEART JOURNAL (2016)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2014)
Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound
Wen-Qian Gao et al.
BMC CARDIOVASCULAR DISORDERS (2014)
Effects of simvastatin/ezetimibe on microparticles, endothelial progenitor cells and platelet aggregation in subjects with coronary heart disease under antiplatelet therapy
L. M. Camargo et al.
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH (2014)
Population pharmacodynamic analysis of LDL-cholesterol lowering effects by statins and co-medications based on electronic medical records
Makoto Kakara et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Statins and the risk of liver injury: a population-based case-control study
Guan-Lin Chen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2014)
Effect of statins on platelet function in patients with hyperlipidemia
Joanna Sikora et al.
ARCHIVES OF MEDICAL SCIENCE (2013)
Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials
Alexios S. Antonopoulos et al.
CURRENT PHARMACEUTICAL DESIGN (2012)
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer - Insights from large randomized statin trials
Alawi A. Alsheikh-Ali et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
The Patient-Reported Outcomes Measurement Information System (PROMIS) Progress of an NIH roadmap cooperative group during its first two years
David Cella et al.
MEDICAL CARE (2007)
Safety profile of rosuvastatin - Results of a prescription-event monitoring study of 11680 patients
Rachna Kasliwal et al.
DRUG SAFETY (2007)
Share Paper
